Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 10,830 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Joseph Douglas Lyon sold 10,830 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $26.00, for a total transaction of $281,580.00. Following the transaction, the insider now owns 7,314 shares of the company’s stock, valued at approximately $190,164. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Joseph Douglas Lyon also recently made the following trade(s):

• On Thursday, April 4th, Joseph Douglas Lyon sold 5,443 shares of Corcept Therapeutics stock. The shares were sold at an average price of $26.00, for a total transaction of $141,518.00.
• On Monday, April 1st, Joseph Douglas Lyon sold 500 shares of Corcept Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $13,005.00.
• On Friday, February 16th, Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $26.00, for a total transaction of $26,000.00.

Corcept Therapeutics Trading Down 2.2 %

Shares of NASDAQ CORT traded down $0.55 during midday trading on Monday, reaching $23.97. 1,230,562 shares of the stock were exchanged, compared to its average volume of 1,472,257. The company has a market capitalization of $2.50 billion, a P/E ratio of 22.61 and a beta of 0.50. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $34.28. The stock has a 50 day moving average price of $23.99 and a 200-day moving average price of $25.15.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.04. Corcept Therapeutics had a net margin of 22.38% and a return on equity of 24.19%. The business had revenue of $146.80 million during the quarter, compared to the consensus estimate of $141.19 million. During the same period in the previous year, the firm posted $0.14 earnings per share. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, analysts forecast that Corcept Therapeutics Incorporated will post 0.97 earnings per share for the current year.

Institutional Investors Weigh In On Corcept Therapeutics

Institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC grew its stake in Corcept Therapeutics by 27.0% during the fourth quarter. Quadrant Capital Group LLC now owns 2,107 shares of the biotechnology company’s stock worth $68,000 after buying an additional 448 shares during the period. Nisa Investment Advisors LLC grew its stake in Corcept Therapeutics by 9.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,900 shares of the biotechnology company’s stock worth $192,000 after buying an additional 500 shares during the period. Linden Thomas Advisory Services LLC grew its stake in Corcept Therapeutics by 1.0% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 56,671 shares of the biotechnology company’s stock worth $1,841,000 after buying an additional 555 shares during the period. GAMMA Investing LLC grew its stake in Corcept Therapeutics by 90.6% during the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after buying an additional 579 shares during the period. Finally, Exchange Traded Concepts LLC grew its stake in Corcept Therapeutics by 1.5% during the fourth quarter. Exchange Traded Concepts LLC now owns 44,448 shares of the biotechnology company’s stock worth $1,444,000 after buying an additional 641 shares during the period. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. HC Wainwright increased their price target on shares of Corcept Therapeutics from $38.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Truist Financial lifted their target price on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $40.10.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.